The Food and Drug Administration Friday authorized the first prescription diagnostic test for both COVID-19 and influenza A and B that allows patients to collect a sample at home and ship it to a laboratory for analysis.

The Quest Diagnostics test received emergency use authorization for use by individuals with a suspected respiratory viral infection consistent with COVID-19 when their health care provider deems home collection appropriate.

“With just one swab or sample, combination tests that are authorized for use with home-collected samples can be used to get answers to Americans faster, in the comfort and relative safety of their home, which allows patients to continue to quarantine while awaiting results,” said FDA Commissioner Stephen Hahn, M.D.

Related News Articles

Headline
Dr. Trestman and Dr. Hochman reflect on the far-reaching effects of the COVID-19 pandemic on the mental health and well-being of health care professionals,…
Headline
The Food and Drug Administration Friday authorized using the monoclonal antibody therapy REGEN-COV for prevention in certain children and adults who are…
Blog
The American Hospital Association and its Society for Healthcare Strategy and Market Development (SHSMD) July 15 hosted “Addressing COVID-19 Vaccine Hesitancy…
Headline
Read a recap and insights from health care leaders during AHA’s July 15 webinar, “Addressing COVID-19 Vaccine Hesitancy in Your Community,” featuring messaging…
Headline
Three-quarters of the 469 COVID-19 cases associated with summer events and large public gatherings this month in Barnstable County, Mass., were in people fully…
Headline
About 8.9 million children aged 12-17 have received the Pfizer COVID-19 vaccine, the Centers for Disease Control and Prevention reported today. Based on data…